TBCT 92
Alternative Names: TBCT-92Latest Information Update: 21 Oct 2020
At a glance
- Originator FibroGenesis
- Class Fibroblast cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cachexia; Cytokine release syndrome
Most Recent Events
- 21 Oct 2020 FibroGenesis has patents pending for fibroblast cell therapy technologies for the treatment of Cachexia and Cytokine release syndrome in USA (FibroGenesis' website, October 2020)
- 21 Oct 2020 Preclinical trials in Cachexia in USA (unspecified route) before October 2020 (FibroGenesis' pipeline, October 2020)
- 21 Oct 2020 Preclinical trials in Cytokine release syndrome in USA (unspecified route) before October 2020 (FibroGenesis' pipeline, October 2020)